Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligation &Disclosure; Requirements) Regulations, 2015

 Pursuant to Regulation 23(9) of Securities and Exchange Board of India (Listing Obligation &Disclosure; Requirements) Regulations, 2015, we hereby submit the disclosure on Related Party Transactions, on standalone basis, prepared in accordance with applicable accounting standards for the half-year ended March 31, 2020.
11-07-2020
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Re-Submission Of Financial Results Due To Discrepancies.

 This is with reference to your mail dated July 03, 2020 for discrepancies in financial Results for the Quarter ended March 2020. Discrepancy: Results Figures are not Clear In this regard we are submitting the clear copy of Financial Results for the quarter ended March 2020. We request you to disseminate the above information on your website.
03-07-2020
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Closure of Trading Window

 The financial results of the Company for the June 30, 2020 will be declared in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. With reference to the above captioned matter, we would like to inform you that pursuant to the Securities & Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Company's Code of Conduct for prohibition of insider trading ('Code') the trading window for dealing in securities of the Company will be closed for the purpose of declaration of Financial Results of the Company for the quarter ended June 30, 2020 for all the Designated person of the Company from Wednesday, July 01, 2020 and shall open 48 hours after announcement of the financial Results, for all its designated persons.
30-06-2020
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayAspira Pathlab & Diagnostics Ltd 2CINL85100MH1973PLC289209 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 7.74 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Mamta Mav Designation: Company Secretary EmailId: info@aspiradiagnostics.com Name of the Chief Financial Officer: Prahlad Bhanushali Designation: Chief Financial Officer EmailId: info@aspiradiagnostics.com Date: 27/06/2020 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
27-06-2020
Bigul

Annual report for Aspira Pathlab & Diagnostics Ltd. for FY-2020
14-06-2020
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Announcement under Regulation 30 (LODR)-Change in Management

 Pursuant to Regulation 30 of the Listing (Obligations & Disclosure Requirements) Regulations, 2015, this is to inform that, the Board of Directors in its meeting held on June 13, 2020 (on the recommendation of the Nomination and Remuneration Committee), approved the re-designation of Dr. Pankaj Shah from Managing Director to Managing Director(MD) and Chief Executive officer(CEO) of the Company.
13-06-2020
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Announcement under Regulation 30 (LODR)-Change in Management

 Pursuant to Regulation 30 of the Listing (Obligations & Disclosure Requirements) Regulations, 2015, this is to inform that, the Board of Directors in its meeting held on June 13, 2020 (on the recommendation of the Nomination and Remuneration Committee), approved the re-designation of Dr. Pankaj Shah from Managing Director to Managing Director(MD) and Chief Executive officer(CEO) of the Company.
13-06-2020
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Annual Audited Financial Results Of The Company For The Quarter And Year Ended 31St March, 2020

 This is to inform you that the Board of Directors of the Company, at their meeting held today at 3 p.m. has Approved the Audited financial results of the Company for the quarter and year ended 31st March, 2020. The above financial Results along with the Auditor's Report on the Financial Results are enclosed herewith. In compliance with the provisions of Regulation 33(3)(d) of the LODR Regulations, the Company hereby declares that the Statutory Auditors of the Company have issued their audit report with unmodified opinion on the Financial Results of the Company for the year ended 31st March, 2020. The meeting of the Board of Directors was concluded at 4.23 p.m. We request you to disseminate the above information on your website.
13-06-2020
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Outcome Of Meeting Of The Board Of Directors Of Aspira Pathlab & Diagnostics Limited

 This is to inform you that the Board of Directors of the Company, at their meeting held today at 3 p.m. has: 1. Approved the Audited financial results of the Company for the quarter and year ended 31st March, 2020. 2. Approved the appointment of S K Pandey, Company Secretary in Practice as Secretarial Auditor of the Company u/s 204 of the Companies Act, 2013 for the financial Year 2020-21. 3. Approved the appointment of Vishal J Bhanushali and Associates, Chartered Accountants as Internal Auditor of the Company for the financial year 2020-21.
13-06-2020
Bigul

Aspira Pathlab & Diagnostics Ltd - 540788 - Disclosure Of Material Impact Of COVID - 19 Pandemic On The Company Under Regulation 30 Read With Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 And SEBI Advisory Vide Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 Dated May 20, 2020

 Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligation & Disclosure Requirements) Regulations, 2015 read with SEBI Advisory vide Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 dated May 20, 2020, we hereby submit an update by the Company giving brief details of the Material Impact of COVID-19 pandemic and the resultant lockdown, on the operations of the Company as an Annexure I. We request you to disseminate the above information on your website.
11-06-2020
Next Page
Close

Let's Open Free Demat Account